SrasV1, PubMed, Corpus, bibRecord, 002030

Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

Identifieur interne : 002030 ( PubMed/Corpus ); précédent : 002029; suivant : 002031

Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

Auteurs : Yuxian He

Source :

Advances in experimental medicine and biology [ 0065-2598 ] ; 2006.

RBID : pubmed:17037594

English descriptors

KwdEn :
- Antibodies, Viral, Epitope Mapping, Epitopes (chemistry), Membrane Glycoproteins (chemistry), Membrane Glycoproteins (physiology), Neutralization Tests, Protein Binding, Protein Conformation, Protein Structure, Tertiary, SARS Virus (metabolism), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (physiology), Viral Vaccines (chemistry).
MESH :
- chemical , chemistry : Epitopes, Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , physiology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical : Antibodies, Viral, Spike Glycoprotein, Coronavirus.
- metabolism : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Epitope Mapping, Neutralization Tests, Protein Binding, Protein Conformation, Protein Structure, Tertiary.

DOI: 10.1007/978-0-387-33012-9_98
PubMed: 17037594

Links to Exploration step

pubmed:17037594

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.</title>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
<affiliation><nlm:affiliation>New York Blood Center, New York, New York 10021, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:17037594</idno>
<idno type="pmid">17037594</idno>
<idno type="doi">10.1007/978-0-387-33012-9_98</idno>
<idno type="wicri:Area/PubMed/Corpus">002030</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002030</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.</title>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
<affiliation><nlm:affiliation>New York Blood Center, New York, New York 10021, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Advances in experimental medicine and biology</title>
<idno type="ISSN">0065-2598</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral</term>
<term>Epitope Mapping</term>
<term>Epitopes (chemistry)</term>
<term>Membrane Glycoproteins (chemistry)</term>
<term>Membrane Glycoproteins (physiology)</term>
<term>Neutralization Tests</term>
<term>Protein Binding</term>
<term>Protein Conformation</term>
<term>Protein Structure, Tertiary</term>
<term>SARS Virus (metabolism)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (chemistry)</term>
<term>Viral Envelope Proteins (physiology)</term>
<term>Viral Vaccines (chemistry)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Epitopes</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Viral</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Epitope Mapping</term>
<term>Neutralization Tests</term>
<term>Protein Binding</term>
<term>Protein Conformation</term>
<term>Protein Structure, Tertiary</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17037594</PMID>
<DateCompleted><Year>2006</Year>
<Month>12</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN>
<JournalIssue CitedMedium="Print"><Volume>581</Volume>
<PubDate><Year>2006</Year>
</PubDate>
</JournalIssue>
<Title>Advances in experimental medicine and biology</Title>
<ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.</ArticleTitle>
<Pagination><MedlinePgn>539-42</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Yuxian</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>New York Blood Center, New York, New York 10021, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Exp Med Biol</MedlineTA>
<NlmUniqueID>0121103</NlmUniqueID>
<ISSNLinking>0065-2598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>12</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17037594</ArticleId>
<ArticleId IdType="doi">10.1007/978-0-387-33012-9_98</ArticleId>
<ArticleId IdType="pmc">PMC7124001</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viral Immunol. 2005;18(2):327-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16035944</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002030 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002030 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:17037594
   |texte=   Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:17037594" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki